Experts fear Treasury's proposed China biotech investment ban will backfire on U.S. leadership

The Proposed Rules and Industry Anxiety

The U.S. Department of the Treasury released a 163-page draft policy detailing how it plans to implement the COINS Act, which seeks to add pharmaceutical compounds to an outbound investment blacklist. While traditional cash-based licensing deals remain untouched, the proposal places ambiguous restrictions on equity investments, co-development deals, and joint ventures involving Chinese entities, leaving biopharma executives and trade attorneys struggling to define compliant behavior.

The Threat of a 'Flying Blind' Strategy

Industry heavyweights, including a coalition of prominent healthcare investors led by RA Capital, argue that the rules will backfire. By barring U.S. investors and drugmakers from engaging in equity and co-commercialization structures in China, American firms will lose vital visibility into the global clinical pipeline. Critics warn that European investors and multinational pharmaceutical companies—unbound by these strict rules—will scoop up promising Chinese assets, leaving U.S. players at a severe disadvantage.

The 'Joint Venture' Riddle and Economic Security

A major source of confusion is the Treasury's lack of a clear legal definition for 'joint ventures,' which threatens popular models like U.S.-based 'NewCos' formed around Chinese-licensed assets. Legal experts note that the broad scope reflects a shifting political reality where economic security is treated as national security. Although the industry is pushing for narrower definitions focused strictly on bioweapons or select agents, analysts suggest that policymakers are determined to protect U.S. technological leadership across the board, regardless of the compliance burden and potential chilling effect on cross-border R&D.